On February 27, 2025, the Emergency Department team at Mercer Health was recognized by the Ohio State University Wexner ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...

In the United States alone, more than 795,000 people experience a stroke each year, which is about one in every 40 seconds, causing 1 in 6 deaths from cardiovascular disease. Globally, stroke is a ...

Coinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Increase the proportion of ischemic stroke patients that receive alteplase or EVT by 5% Reduce the time to treatment for both alteplase and EVT Reduce the door-to-needle time for alteplase treatment ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires ...

As stroke remains one of the leading causes of long-term disability and death worldwide, finding a more efficient and effective treatment is critical for improving patient outcomes and reducing ...